Advertisement
More than 2,500 reader votes were cast in this inaugural competition, and Alnylam/Takeda led the polling from start to finish among the 13 nominees selected by The IN VIVO Blog's writers and editorial team at FDC-Windhover, an Elsevier company.
Advertisement
"In a time when investment capital is frozen, winning biotechs are figuring out ways of non-dilutively funding their operations -- not simply by avoiding selling cheap equity but avoiding the sale of product rights as well," said Roger Longman, Managing Director, FDC-Windhover. "Alnylam has managed to monetize its technology base without fundamentally restricting its own product opportunities or diluting its investors -- with its Takeda deal a perfect example of how it pulls off this impressive feat."
"The deal allows Alnylam to end the year with approximately $500 million in cash and sets the RNAi pioneer up for pipeline building down the road. And as for Takeda: it's now the sole big RNAi player in Japan and cements this pharma's place among the most active and creative dealmakers of 2008," Longman said.
For more information, including an explanation of how the nominees were selected for The IN VIVO Blog's Deal of the Year and some commentary from the winner, please visit http://invivoblog.blogspot.com/.
To speak with someone at The IN VIVO Blog about this award, please contact Tom Reller, Elsevier, 212.462.1912 or email [email protected].
SOURCE FDC-Windhover
